Abstract
The present study was conducted to assess correlation of ammonia levels with valproate levels in epileptic patients presenting with valproate toxicity and also whether liver enzymes and ammonia levels could serve as biochemical marker of valproate toxicity. 100 patients with epilepsy who had received valproate therapy for more than 12 months and had presented with valproate toxicity and 100 controls were included in the study. The serum valproate, ammonia and liver enzymes were measured in these subjects. In patients with valproate toxicity, the mean level of serum valproate was 110.91 ± 28.68 mg/dL (therapeutic range 50–100 mg/dL). Serum ammonia was higher (86.37 ± 39.90 µg/dL) in patients with valproate toxicity compared to controls (68.73 ± 30.07 µg/dL). Out of 100 patients, only 37 patients had serum valproate level > 120 mg/dL and 22 patients had raised levels of valproate as well as ammonia. Age < 30 years and serum ammonia > 69 μg/dL is risk factors for valproate toxicity. Serum ammonia, liver enzymes should be regularly investigated in patients on valproate therapy for early diagnosis of valproate toxicity.
Similar content being viewed by others
References
Schmidt D. Adverse effect of valproate. Epilepsia 1984; 25(Suppl 1): S44–S49.
Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurol 1987; 37(3): 379–385.
Jeavons PM. Non-dose-related side effects of valproate. Epilepsia 1984; 25(Suppl 1): S50–S55.
Blindauer KA, Harrington G, Morris GL 3rd, Ho KC. Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurol 1998; 51(1): 292–295.
Hamer HM, Knake S, Schomburg U, Rosenow F. Valproateinduced hyperammonemic encephalopathy in the presence of topiramate. Neurol 2000; 54(1): 230–232.
Schobben F, van der Kleijn E, Gabreels FJM. Pharmacokinetics of di-N-propylacetate in epileptic patients. Euro J Clin Pharmacol 1975; 8: 97–105.
Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006; 114(1): 1–7.
Koch-Weser J, Browne TR. Drug therapy: Valproic acid. N Engl J Med 1980; 302(12): 661–666.
Ratnaike RN, Schapel GJ, Purdie G, Rischbieth RHC, Sheryl H. Hyperammonaemia & hepatotoxicity during chronic valproate therapy: enhancement of combination with other antiepileptic drugs. Br J Clin Pharmac 1986; 22: 100–103.
Warter JM, Imler M, Marcscaux C, Chabrier G, Rumbach L, Micheletti G, Krieger J. Sodium valproate induced hyperammonemia in the rat: role of kidney. Eur J Pharmac 1983; 87: 177–182.
Coude FX, Grimer G, Parvy P, Rabir D, Petit F. Inhibition of ureagenesis by valproate in rat hepatocytes. Biochem J 1983; 216: 233–236.
Beghi E, Bizzi A, Codegoni AM, Trevisan D, Torri W. Valproate, carnitine metabolism, and biochemical indicators of liver function. Collaborative Group for the Study of Epilepsy. Epilepsia 1990; 31(3): 346–352.
Laub MC. Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 1986; 27(1): 55–59.
Rath A, Narayanan T, Jaishree, Chowdhary GVS, Murthy JMK. Valproate induced hyperammonaemia encephalopathy with normal liver function. Neurology India 2005; (53): 226–228.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Agarwal, R., Sharma, S., Chhillar, N. et al. Hyperammonemia and hepatic status during valproate therapy. Indian J Clin Biochem 24, 366–369 (2009). https://doi.org/10.1007/s12291-009-0066-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-009-0066-2